BioCentury
ARTICLE | Clinical News

2B3-101: Phase I/IIa ongoing

September 2, 2013 7:00 AM UTC

to-BBB began the Phase IIa portion of an open-label, dose-escalation, European Phase I/IIa trial to evaluate IV 2B3-101 in about 82 patients with recurrent malignant glioma and patients with brain met...